Search Results - "Pacaud, Lida B"

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Schuster, Stephen J, Bishop, Michael R, Tam, Constantine S, Waller, Edmund K, Borchmann, Peter, McGuirk, Joseph P, Jäger, Ulrich, Jaglowski, Samantha, Andreadis, Charalambos, Westin, Jason R, Fleury, Isabelle, Bachanova, Veronika, Foley, S. Ronan, Ho, P. Joy, Mielke, Stephan, Magenau, John M, Holte, Harald, Pantano, Serafino, Pacaud, Lida B, Awasthi, Rakesh, Chu, Jufen, Anak, Özlem, Salles, Gilles, Maziarz, Richard T

“…The capacity to use CAR T-cell therapy has been limited by the need to produce cells in a specialized laboratory. In this study, 40% of patients with relapsed…”
Get full text

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma by Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Tam, Constantine S.

“…The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma…”
Get full text

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Juliet Trial by Jaeger, Ulrich, Bishop, Michael R., Salles, Gilles, Schuster, Stephen J., Maziarz, Richard T., Han, Xia, Savchenko, Alexander, Roscoe, Nathan, Orlando, Elena, Knoblock, Dawson, Tiwari, Ranjan, Pacaud, Lida B., Corradini, Paolo

Get full text

Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 by Hurvitz, Sara A, Andre, Fabrice, Jiang, Zefei, Shao, Zhimin, Neciosup, Silvia P, Mano, Max S, Tseng, Ling-Min, Zhang, Qingyuan, Shen, Kunwei, Liu, Donggeng, Dreosti, Lydia M, Feng, Jifeng, Burris, Howard A, Toi, Masakazu, Buyse, Marc E, Cabaribere, David, Lindsay, Mary-Ann, Kunz, Tiffany, Rao, Shantha, Pacaud, Lida B, Taran, Tetiana, Slamon, Dennis

“…Abstract Background: Everolimus (EVE), an inhibitor of mammalian target of rapamycin (mTOR), is a protein kinase central to a number of signaling pathways…”
Get full text

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial by Fowler, Nathan, Dickinson, Michael, Dreyling, Martin, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P Joy, Pérez Simón, José Antonio, Nagle, Sarah, Nastoupil, Loretta J., von Tresckow, Bastian, María Ferreri, Andrés José, Teshima, Takanori, Patten, Piers EM, McGuirk, Joseph P, Petzer, Andreas, Offner, Fritz, Viardot, Andreas, Zinzani, Pierluigi, Malladi, Ram, Pacaud, Lida B., Forcina, Alessandra, Zia, Aiesha, Schuster, Stephen J., Thieblemont, Catherine

Get full text

Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study by Tam, Constantine S., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Teshima, Takanori, Bachanova, Veronika, Foley, Stephen Ronan, Borchmann, Peter, Salles, Gilles A., Anak, Oezlem, Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Maziarz, Richard T.

“…Quality of life (QoL) is an important endpoint in the JULIET study (NCT02445248), a phase 2 trial evaluating a single infusion of tisagenlecleucel in adult…”
Get full text